# Santen Inc. clinical trials: 32 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Santen Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Santen Inc.: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/santen-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 27, 2022 | NCT05665387 | Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia | Santen Inc. | Phase 2 | Completed | Presbyopia | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05665387) |
| May 17, 2022 | NCT05376176 | A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects... | Santen Inc. | Phase 2 | Completed | Fuchs Endothelial Corneal Dystrophy | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05376176) |
| February 8, 2021 | NCT04742283 | Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution... | Santen Inc. | Phase 2 | Completed | Primary Open Angle Glaucoma, Ocular Hypertension | 323 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04742283) |
| March 1, 2019 | NCT03858894 | Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle... | Santen Inc. | Phase 2 | Completed | Primary Open-angle Glaucoma and Ocular Hypertension | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03858894) |
| October 19, 2018 | NCT03711929 | LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active... | Santen Inc. | Phase 3 | Terminated | Non Infectious Uveitis | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03711929) |
| October 5, 2018 | NCT03697811 | DE-117 Spectrum 5 Study | Santen Inc. | Phase 3 | Completed | Primary Open-angle Glaucoma and Ocular Hypertension | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03697811) |
| October 2, 2018 | NCT03691662 | A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in... | Santen Inc. | Phase 3 | Completed | Glaucoma and Ocular Hypertension | 417 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03691662) |
| October 2, 2018 | NCT03691649 | A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in... | Santen Inc. | Phase 3 | Completed | Glaucoma and Ocular Hypertension | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03691649) |
| July 13, 2017 | NCT03216902 | A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study | Santen Inc. | Phase 2 | Completed | Open-angle Glaucoma, Ocular Hypertension | 241 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03216902) |
| July 7, 2017 | NCT03211234 | Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis®... | Santen Inc. | Phase 2 | Completed | Age-Related Macular Degeneration | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03211234) |
| September 21, 2015 | NCT02555306 | A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related... | Santen Inc. | Phase 1/2 | Completed | Age-Related Macular Degeneration | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02555306) |
| March 30, 2015 | NCT02401945 | A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration | Santen Inc. | Phase 2 | Completed | Age-Related Macular Degeneration | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02401945) |
| September 29, 2014 | NCT02251938 | A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of... | Santen Inc. | Phase 3 | Completed | Non-Infectious Uveitis of the Posterior Segment of the Eye | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02251938) |
| July 1, 2014 | NCT02179008 | Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or... | Santen Inc. | Phase 2 | Completed | Open-angle Glaucoma, Ocular Hypertension | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02179008) |
| December 27, 2013 | NCT02022501 | A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration | Santen Inc. | Phase 1/2 | Completed | Age-Related Macular Degeneration | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02022501) |
| June 4, 2013 | NCT01868126 | Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular... | Santen Inc. | Phase 2 | Completed | Open-angle Glaucoma or Ocular Hypertension | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01868126) |
| July 31, 2012 | NCT01654484 | A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT | Santen Inc. | Phase 1/2 | Completed | Glaucoma and Ocular Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01654484) |
| November 9, 2011 | NCT01468168 | A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients | Santen Inc. | Phase 2 | Completed | Dry Eye Disease | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01468168) |
| May 23, 2011 | NCT01358266 | Study Assessing Double-masked Uveitis Treatment | Santen Inc. | Phase 3 | Completed | Uveitis; Posterior, Disorder | 592 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01358266) |
| January 19, 2011 | NCT01279083 | Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension | Santen Inc. | Phase 1/2 | Completed | Open-angle Glaucoma, Ocular Hypertension | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01279083) |
| November 11, 2010 | NCT01239069 | Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease | Santen Inc. | Phase 2 | Completed | Dry Eye | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01239069) |
| May 7, 2010 | NCT01118754 | Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients | Santen Inc. | Phase 1/2 | Completed | Dry Eye | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01118754) |
| March 25, 2009 | NCT00868894 | Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension | Santen Inc. | Phase 1/2 | Completed | Open-Angle Glaucoma, Ocular Hypertension | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00868894) |
| December 25, 2008 | NCT00814944 | A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the... | Santen Inc. | Phase 2 | Completed | Dry Eye | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00814944) |
| October 3, 2008 | NCT00766337 | Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration | Santen Inc. | Phase 2 | Terminated | Age-Related Macular Degeneration, Choroidal Neovascularization | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00766337) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 7 |
| Phase 2 | 15 |
| Phase 3 | 6 |
| Phase 4 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Terminated | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ocular Hypertension | 12 |
| Glaucoma, Open-Angle | 9 |
| Glaucoma | 7 |
| Macular Degeneration | 6 |
| Dry Eye Syndromes | 4 |
| Choroidal Neovascularization | 2 |
| Fuchs' Endothelial Dystrophy | 1 |
| Diabetic Retinopathy | 1 |
| Presbyopia | 1 |
| Cataract | 1 |
| Uveitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [General dentistry practices in the United States](https://specstream.ai/data/businesses/general-dentistry-practices/united-states)
- [B2B food products companies in the United States](https://specstream.ai/data/businesses/b2b-food-products-companies/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
